BURNETT JOSEPH sold $388K of CLPT

BURNETT JOSEPH (CEO and President) sold 20,000 shares of ClearPoint Neuro, Inc. (CLPT) at $19.38 ($0.39M total) on 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BURNETT JOSEPH
Published Jul 1, 2026, 10:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 10:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLPT
Neutral
medium confidence
Mentioned
$CLPT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLPTNeutralLow
01

Why it matters

The newest disclosed fact is the specific open-market sale (20,000 shares at $19.38) and the post-transaction holdings, which can marginally influence sentiment but does not change fundamentals by itself.

02

Market read

This is a fresh insider-sale datapoint; it may matter for short-term sentiment but is unlikely to drive a fundamental repricing alone.

03

What to watch

Traders may overreact to the headline sale size; the key nuance is the 10b5-1 pre-arrangement, which often dampens signal quality.

Relevance 3/10Novelty 6/10Timing: today’s SEC Form 4 disclosure (filed 2026-07-01)

Background

The article is an SEC Form 4 insider transaction for ClearPoint Neuro, Inc. (CLPT) by CEO/President Joseph Burnett.

Company-level read

Ticker impact

$CLPTNeutralMedium confidence
Context

ClearPoint Neuro CEO Joseph Burnett sold 20,000 shares in an open-market transaction at $19.38 on 2026-06-29, per Form 4.

Expected impact

Likely limited immediate price impact; any effect would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a primary-source Form 4 showing a sizable sale, but it explicitly states a pre-arranged 10b5-1 plan, which reduces interpretive weight.

Market effects

No sector-wide implications; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.

Key entities

  • ClearPoint Neuro, Inc.

    Subject of the Form 4 insider sale disclosed in the article.

  • Joseph Burnett

    CEO and President who sold 20,000 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CLPTMed

ClearPoint Neuro (CLPT) Q3 2026 Earnings Call Transcript

ClearPoint Neuro (CLPT) reported Q3 2026 revenue of $12.1M, up 36% YoY, driven by growth in neurosurgery navigation and capital equipment sales. The company used its ATM facility to raise $22M, ending the quarter with $46.2M in cash. CLPT supports uniQure's BLA submission for Huntington's disease treatment, aiming for parallel FDA approvals. The company is preparing for increased Phase III trials and commercial product launches in 2027.

$CLPTMed

What ClearPoint Neuro (CLPT) Said on Its Q3 Earnings Call

ClearPoint Neuro (CLPT) reported Q3 operating expenses of $13.4M, down from $17M in Q2. Cash reserves were $46.2M, with $22M raised via equity offering. CEO Burnett expects reduced operating burn and capital expenditures. The company awaits FDA decision on AMT-130 submission, with potential parallel approvals for drug and device. ClearPoint outlined four growth pillars, including biologics, neurosurgery navigation, and laser therapy.

$CLPTMed

ClearPoint Neuro Reports Third Quarter 2026 Results

ClearPoint Neuro, Inc. (CLPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ClearPoint Neuro Reports Third Quarter 2026 Results Neurosurgery Navigation & Therapy Grew 59% to $5.4 Million SOLANA BEACH, CA, October 28, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offerin